Bologna

• A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel … Ended
  2023-509155-14-00 4 2021-06-10 Peripheral T-cell Lymphoma
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-507977-16-00 4 2021-05-10 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• Isatuximab in combination with pegenzileukin in RRMM previously exposed to anti-CD38 and anti- BCMA Ended
  2024-514990-23-00 9 2021-03-31 Cancer
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• A Clinical Trial to Test the Safety, Effect, and Activity of Rilzabrutinib (PRN1008) in Adult and Adolescent Patients with Persistent or Chr … Ended
  2023-509401-71-00 5 2021-02-05 Immune Thrombocytopenia (ITP)
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid … Ended
  2024-512469-15-00 9 2020-12-08 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Po
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20 Relapsed or Refractory Multiple Myeloma
• A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in … Ended
  2024-515424-36-00 4 2020-10-15 Acute Myeloid Leukemia
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL … Ended
  2023-509270-37-00 7 2019-10-10 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and
• A Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformatio … Ended
  2024-516675-32-00 4 2019-10-08 Richter syndrome of chronic lymphocytic leukemia
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Inves … Ended
  2024-512967-29-00 4 2019-09-03 Hypoparathyroidism (HP) in Adults
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended
  2024-515929-28-00 4 2019-08-02 Non-small Cell Lung Cancer
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 5 2019-06-12 Multiple myeloma (MM) with at least 2 prior therapies including an imm

Showing 817–840 of 868 trials